[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100621231":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":11,"centralContacts":28,"locations":11,"responsibleParty":38,"collaborators":11,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":11,"eligibilityCriteria":48,"healthyVolunteers":44,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":11,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":66,"whyStopped":11,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":11},{"fullName":5,"class":6},"Cairo University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Crisaborole ointment","ACTIVE_COMPARATOR",null,[13],"Drug: Application of crisaborole twice daily",{"label":15,"type":10,"description":11,"interventionNames":16},"Tacrolimus ointment",[17],"Drug: Tacrolimus ointment in atopic dermatitis",[19,24],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","Application of crisaborole twice daily","compare the efficacy and safety of crisaborole ointment on mild to moderate atopic dermatitis for 1 month and followup in 2 months",[9],{"type":20,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"Tacrolimus ointment in atopic dermatitis","compare the efficacy and safety of tacrolimus ointment, in the treatment of patients with mild-to-moderate atopic dermatitis",[15],[29,34],{"name":30,"role":31,"phone":32,"phoneExt":11,"email":33},"Aya Raafat Khalil, MBBcH","CONTACT","+201120807903","ayah.rafaat.97@gmail.com",{"name":35,"role":31,"phone":36,"phoneExt":11,"email":37},"Rana Ahmed Mosaad, MD","+201096344429","ranaahmedmosaad@gmail.com",{"type":39,"investigatorFullName":40,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Amira Elbendary","Lecturer","100621231","phase-4-comparative-study-of-crisaborole-vs-tacrolimus-in-atopic-dermatitis-100621231",false,"NCT07367932","Comparative Study of Crisaborole vs. Tacrolimus in Atopic Dermatitis","Crisaborole 2% Versus Tacrolimus 0.03% Ointments for the Treatment of Mild to Moderate Atopic Dermatitis: A Comparative Study","Inclusion Criteria:\n\n* Patients with diagnosis of AD, according to Hanifin and Rajka criteria.\n* Patients of both genders\n* Age 5-25 years\n* Baseline Investigator's Static Global Assessment (ISGA) score of mild (2) or moderate (3).\n\nExclusion Criteria:\n\n* Clinically infected eczema.\n* Baseline Investigator's Static Global Assessment (ISGA) score of severe (4).\n* Associated comorbidities that exacerbate pruritus.\n* Patients receiving topical treatment for AD and\u002For pruritus within the past 14 days and\u002For systemic treatment within the past month.\n* Pregnancy and lactation if in the childbearing period","ALL","5 Years","25 Years",{"count":53,"type":54},30,"ESTIMATED","INTERVENTIONAL",[57],"PHASE4","This study will compare the efficacy and safety of crisaborole ointment with tacrolimus ointment, in the treatment of patients with mild-to-moderate atopic dermatitis.",[60,61],"Dermatitis, Atopic","Eczema",[63,64,65],"Tacrolimus","Crisaborole","Atopic dermatitis","NOT_YET_RECRUITING","2026-01-20",{"date":69,"type":70},"2026-01-26","ACTUAL",{"date":72,"type":54},"2026-02",{"date":74,"type":54},"2026-07",{"name":5,"class":6}]